A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
- Conditions
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 900
- Registration Number
- NCT02960022
- Locations
- 🇫🇷
Site FR33021, Bordeaux Cedex, France
🇺🇸Site US10052, Anchorage, Alaska, United States
🇺🇸Site US10011, Tucson, Arizona, United States
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
- First Posted Date
- 2016-10-07
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT02927262
- Locations
- 🇫🇷
Site FR33014, Vandoeuvre les Nancy, Meurthe-et-Moselle, France
🇬🇧Site GB44007, Exeter, Devon, United Kingdom
🇯🇵Site JP81011, Tachikawa, Tokyo, Japan
Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients
- First Posted Date
- 2016-10-03
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT02921789
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Washington University in St. Louis, Saint Louis, Missouri, United States
A Study to Evaluate the Pharmacokinetics of ASP1707 and Methotrexate in Patients With Rheumatoid Arthritis
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02867306
- Locations
- 🇲🇩
Site MD37301, Chisinau, Moldova, Republic of
A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT02864290
- Locations
- 🇺🇸
Site US00007, Boston, Massachusetts, United States
🇺🇸Site US00009, Boston, Massachusetts, United States
🇨🇦Site CA00010, Toronto, Ontario, Canada
A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine
- Conditions
- Interventions
- First Posted Date
- 2016-08-01
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT02851277
- Locations
- 🇺🇸
Site US10014, Little Rock, Arkansas, United States
🇺🇸Site US10001, Baltimore, Maryland, United States
🇺🇸Site US10008, Mountain View, California, United States
A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance
- First Posted Date
- 2016-06-15
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 227
- Registration Number
- NCT02799745
- Locations
- 🇺🇸
Site US10038, Chicago, Illinois, United States
🇺🇸Site US10056, Dallas, Texas, United States
🇨🇦Site CA15003, Toronto, Ontario, Canada
A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
- Conditions
- Interventions
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 715
- Registration Number
- NCT02757768
- Locations
- 🇺🇸
Site US01009, Homewood, Alabama, United States
🇺🇸Site US01005, Huntsville, Alabama, United States
🇺🇸Site US01070, Hawaiian Gardens, California, United States
A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 183
- Registration Number
- NCT02752035
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸UCLA David Geffen School of Medicine, Los Angeles, California, United States
To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 599
- Registration Number
- NCT02723591
- Locations
- 🇺🇸
Site US10025, Scottsdale, Arizona, United States
🇺🇸Site US10037, New York, New York, United States
🇺🇸Site US10002, Charleston, South Carolina, United States